| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
GABA-transaminase[1]
γ-Acetylenic GABA hydrochloride targets GABA-transaminase, the enzyme responsible for the degradation of GABA. By irreversibly inhibiting GABA-transaminase, the compound increases GABA levels in the brain. GABA is the chief inhibitory neurotransmitter in the central nervous system. |
|---|---|
| ln Vitro |
In vitro activity data for γ-Acetylenic GABA hydrochloride show that it is an irreversible inhibitor of GABA-transaminase. The compound inhibits GABA-transaminase activity. It is a click chemical reagent due to the presence of an alkyne group.
|
| ln Vivo |
γ-Acetylenic GABA hydrochloride (100 mg/kg ip) increases the amount of GABA in the rat brain several times over and inhibits GABA-transaminase activity[2].
γ-Acetylenic GABA hydrochloride (100 mg/kg i.p.) inhibits GABA-transaminase activity and causes a several-fold increase in the concentration of GABA in rat brain. This in vivo activity demonstrates the compound's efficacy in raising brain GABA levels. |
| Enzyme Assay |
The in vitro enzyme assay for γ-Acetylenic GABA hydrochloride involves measuring its inhibition of GABA-transaminase activity. Recombinant GABA transaminase is incubated with GABA as a substrate. The production of succinic semialdehyde is monitored. γ-Acetylenic GABA hydrochloride is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for γ-Acetylenic GABA hydrochloride typically use neuronal cell lines to assess its effects on GABA levels. Cells are treated with the compound at various concentrations. GABA levels in the cell lysate or medium are measured using HPLC or ELISA.
|
| Animal Protocol |
γ-Acetylenic GABA hydrochloride has been used in vivo in animal models. At 100 mg/kg i.p., it inhibits GABA-transaminase activity and causes a several-fold increase in GABA concentration in rat brain. The compound has been studied in the context of tardive dyskinesia.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of γ-Acetylenic GABA hydrochloride are not extensively documented. As a small molecule with a molecular weight of 163.60, the compound is expected to have reasonable bioavailability. Its alkyne group may influence its metabolism. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for γ-Acetylenic GABA hydrochloride are not extensively available in the public domain. As a research compound, it has not undergone extensive toxicological evaluation. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further preclinical toxicology studies would be required before clinical development.
|
| References | |
| Additional Infomation |
γ-Acetylenic GABA hydrochloride (GAG hydrochloride) is an irreversible inhibitor of GABA-transaminase. It increases GABA concentration in rat brain. The compound has a molecular weight of 163.60. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C6H10CLNO2
|
|---|---|
| Molecular Weight |
163.60
|
| Exact Mass |
163.04
|
| CAS # |
103451-26-9
|
| PubChem CID |
86740723
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
10
|
| Complexity |
144
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C#CC(CCC(=O)O)N.Cl
|
| InChi Key |
ZAVKUGNSMAPIEF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H9NO2.ClH/c1-2-5(7)3-4-6(8)9;/h1,5H,3-4,7H2,(H,8,9);1H
|
| Chemical Name |
4-aminohex-5-ynoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1125 mL | 30.5623 mL | 61.1247 mL | |
| 5 mM | 1.2225 mL | 6.1125 mL | 12.2249 mL | |
| 10 mM | 0.6112 mL | 3.0562 mL | 6.1125 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
